Schering PEG-Intron/Rebetol committee update
Executive Summary
FDA's Antiviral Drugs Advisory Committee will receive an update on the approval of Schering-Plough's PEG-Intron (peginterferon alfa-2b) for use alone or in combination with Rebetol (ribavirin) for treatment of hepatitis C at its Dec. 12 meeting. PEG-Intron was approved for combination therapy with Rebetol in August with certain postmarketing study commitments (1"The Pink Sheet" Aug. 20, p. 24). The meeting will begin at 8:15 a.m. at the Holiday Inn in Bethesda, Md...